Last €4.83 EUR
Change Today -0.142 / -2.86%
Volume 150.0
9EY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 3:54 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

endocyte inc (9EY) Snapshot

Open
€4.83
Previous Close
€4.97
Day High
€4.83
Day Low
€4.80
52 Week High
03/21/14 - €29.05
52 Week Low
07/29/14 - €4.35
Market Cap
200.5M
Average Volume 10 Days
1.2K
EPS TTM
--
Shares Outstanding
41.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDOCYTE INC (9EY)

endocyte inc (9EY) Related Businessweek News

No Related Businessweek News Found

endocyte inc (9EY) Details

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is primarily developing vintafolide, a SMDC that targets the platinum-resistant ovarian cancer, non-small cell lung cancer, triple negative breast cancer, and carboplatin/paclitaxel combination; and etarfolatide, a proprietary companion imaging agent for vintafolide. The company is also developing product candidates for colorectal, prostate, kidney, endometrial, solid tumors, and other cancers, as well as for chronic inflammatory disorders. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.

91 Employees
Last Reported Date: 03/5/14
Founded in 1995

endocyte inc (9EY) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $722.0K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $212.2K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $434.4K
Executive Officer
Total Annual Compensation: $477.8K
Vice President of Clinical Affairs
Total Annual Compensation: $435.6K
Compensation as of Fiscal Year 2013.

endocyte inc (9EY) Key Developments

Brower Piven Announces Class Action Lawsuit on Behalf of Purchasers of Endocyte

Brower Piven announced that a class action lawsuit has been commenced in the United States District Court for the Southern District of Indiana on behalf of purchasers of Endocyte, Inc. common stock during the period between March 21, 2014 and May 2, 2014, inclusive, and informs investors who wish to become proactively involved in the litigation that they have until August 25, 2014 to seek appointment as lead plaintiff. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If wish to choose counsel to represent and the Class, must apply to be appointed lead plaintiff no later than August 25, 2014 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the large loss from investment in Company units during the Class Period.

Endocyte, Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Revenue Guidance for the Third Quarter and Fourth Quarter of Fiscal 2014 and Provides Capital Expenditure Guidance for Fiscal 2014

Endocyte, Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. Endocyte reported net income of $22.4 million, or $0.54 per basic share and $0.52 per diluted share, for the second quarter of 2014, compared to a net loss of $8.2 million, or $0.23 per basic and diluted share, for the same period in 2013. Revenue was $49.2 million for the second quarter of 2014 associated with the collaboration with Merck against $16.5 million for the same period of last year. As a result of the termination of the PROCEED trial and collaboration agreement with Merck, Endocyte accelerated recognition of the previously deferred collaboration revenue. Net cash outflow from operations for the second quarter of 2014 was $14.2 million compared to $17.4 million in the first quarter of 2014 and $16.1 million in the second quarter of 2013. Income from operations was $22.2 million against loss of $8.3 million for the same period of last year. For the six months, the company reported net income of $19.2 million, or $0.47 per diluted share, for the second quarter of 2014, compared to a net loss of $12.1 million, or $0.34 per diluted share, for the same period in 2013. Revenue was $66.44 million against $31 million for the same period of last year. Income from operations was $18.99 million against loss of $12.3 million for the same period of last year. The company expects third quarter revenue will wind down to the $3 million to $5 million range, and then being near 0 in the fourth quarter. That $3 million to $5 million estimate includes PROCEED and TARGET trial activities during the period, first; and second, the reimbursement of past expenses, which will go beyond the original agreement with Merck, which it had not recognized as revenue yet; and all the future trial expenses that Merck will reimburse. With the June ending cash balance of $219 million, the company revised cash balance at the end of 2014 in excess of $200 million represents a significant reduction in the roughly $15 million to $16 million quarterly cash burn rate it had experienced recently. This will result from both a reduction in expense, as the second half expenses will be down from last year by about 1/3, and also the timing of reimbursements from Merck, as they'll be paying for in the quarter those expenses that were recognized in prior periods and actually paying for expenses that, from a cash standpoint, will actually occur in future periods.

Endocyte, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 12:45 PM

Endocyte, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 12:45 PM. Venue: Le Parker Meridien, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
9EY:GR €4.83 EUR -0.142

9EY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 9EY.
View Industry Companies
 

Industry Analysis

9EY

Industry Average

Valuation 9EY Industry Range
Price/Earnings 18.8x
Price/Sales 2.7x
Price/Book 1.3x
Price/Cash Flow 20.3x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOCYTE INC, please visit www.endocyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.